https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/
Iovance reported second-quarter 2026 results on August 6, 2026. Total product revenue reached a record ~$99.3 million, ahead of the $86 million to $88 million range management guided in May, with the earnings call held at 8:30 a.m. ET.
https://www.merlintrader.com/tvtx-vs-vera-iga-nephropathy-stock-comparison/
Travere Therapeutics and Vera Therapeutics look easy to compare: both operate in rare kidney disease, both have major exposure to IgA nephropathy, and their lead products will increasingly appear in front of the same nephrologists. In reality, an investor choosing between them is selecting two almost opposite risk profiles. TVTX offers FILSPARI, meaningful existing revenue, two FDA-approved indications, a fast-starting FSGS launch and a more diversified pipeline, but it comes with a valuation close to $6 billion and a substantial convertible-debt burden. VERA trades at less than half Travere’s market value, owns a potentially powerful immunology franchise and retains worldwide rights to TRUTAKNA, but it is only now entering its commercial phase, still burns significant capital and faces a looming BAFF/APRIL competitor backed by Vertex. The useful question is not which company wins, but what actually has to happen for each equity to create value from here.
https://www.merlintrader.com/moderna-stock-hub/
Moderna’s investment thesis changed materially on August 19, 2026. The pivotal INTerpath-001 study of individualized neoantigen therapy intismeran autogene plus Merck’s KEYTRUDA achieved its reported Phase 3 efficacy objectives in high-risk resected melanoma. The result gives Moderna its strongest late-stage therapeutic validation outside infectious disease, while FDA approval of MFLUSIVA, a broader respiratory portfolio and billions of dollars in liquidity provide additional strategic depth. The remaining debate is no longer whether Moderna can produce a meaningful non-COVID late-stage signal. It is whether the company can convert that scientific validation into regulatory approvals, scalable personalized manufacturing, durable revenue and sustainable cash economics.
On August 17 every party in the DEA rescheduling case filed its post-hearing brief. The Government asked for Schedule III. Every outside designated party argued that marijuana should remain in Schedule I. Here is what the documents actually say, what happens next, what the sector reported while the lawyers wrote, and which dates are real.
Amylyx has crossed the biggest clinical hurdle in its current story. Phase 3 LUCIDITY showed a 55% reduction versus placebo in the FDA-agreed composite rate of Level 2 and Level 3 hypoglycemic events, with p=0.000003 and all reported secondary endpoints met. The debate now moves from pivotal efficacy risk toward FDA execution, label scope, commercialization, pricing, reimbursement and whether avexitide can establish the first approved treatment franchise in post-bariatric hypoglycemia.
ABCL635 produced an 83% week-4 reduction in moderate-to-severe hot-flash frequency versus 33% on placebo, with no serious adverse events or liver signal. One day later AbCellera launched a proposed US$200 million primary offering of common shares and pre-funded warrants to fund ABCL635 and general corporate purposes. The offering priced on August 12 at US$9.75 per share: 17,435,897 common shares plus pre-funded warrants for a further 3,076,926 shares, US$200.0 million gross, with delivery on or about August 14.
EyePoint’s first pivotal Phase 3 in wet AMD missed its primary endpoint on the full dataset and recovered non-inferiority only by excluding nine patients out of 211. The stock lost roughly seventy per cent. Every other company in the durability race went up. Both facts are informative, and they do not say the same thing.
https://www.merlintrader.com/rocket-lab-stock-hub/
Rocket Lab now combines a record operating quarter with the most consequential financing decision in its history. The preliminary Iridium S-4 puts numbers around the acquisition, the pro forma balance sheet and the potential stock leg; the August 13 equity programme shows how management may reduce the bridge. The operating business is compounding fast and still loses money, while Neutron remains the industrial hinge of the thesis.
IREN owns power-connected data centre capacity and is converting it from Bitcoin mining to contracted AI cloud services. The handover is visible quarter by quarter: AI Cloud revenue has roughly doubled each quarter while mining revenue has more than halved, and total revenue is falling while it happens.
Eton has crossed from approval-driven micro-cap into a profitable rare-disease commercial platform. The operating evidence is now much stronger; after a 44% post-earnings move, the burden of proof has shifted to sustained execution, margin quality and dilution-aware valuation.
Capricor changed the shape of a near-term FDA event without securing approval, AbCellera produced a clean four-week Phase 2 signal in vasomotor symptoms, and Definium delivered its second positive Phase 3 study. The rest of the week was just as consequential: pivotal failures at Tenax and Sionna, a strategic retreat at PDS Biotech, two FDA approvals, new trial clearances, commercial acceleration and a bankruptcy asset auction.
https://www.merlintrader.com/sidus-space-stock-hub/
The Q2 filing confirms $166.5 million of cash, $167.6 million of working capital and no debt. It also shows $583 thousand of revenue, a negative 108% gross margin and a $5.08 million adjusted EBITDA loss. Financing risk fell; the commercialization test became harder.
https://www.merlintrader.com/lifeward-ltd-stock-hub/
Last dated event — reported by the company
Q2 2026 results, August 14, 2026
Revenue rose 16% to $6.623 million, the strongest quarter since the fourth quarter of 2024, and unrestricted cash stood at $9.448 million at June 30, 2026 against approximately $11 million on a pro-forma basis after the July tranche. The same filing disclosed the resignation of three directors effective August 13 and the departure of the chief financial officer effective September 30. The reported net loss widened to $11.519 million because of a $6.912 million non-cash fair-value remeasurement of warrant and derivative liabilities. Figures from the Form 8-K and Exhibit 99.1 filed August 14, 2026, and the Q2 2026 Form 10-Q.
https://www.merlintrader.com/unusual-machines-umac-stock-hub/
Verified through August 14, 2026: second-quarter revenue reached $16.72 million, up 687% year on year and 106% sequentially, while the company built a $316.37 million cash-and-investment position. The operating record is less mature than the balance sheet: Q2 GAAP operating loss was $7.81 million, first-half operating cash use was $38.89 million, shares outstanding rose 32% in six months, and the pending Upgrade Energy transaction plus a proposed five-million-warrant CEO award create further dilution and integration questions. The August 13 drone-tariff proclamation can accelerate domestic substitution, but UMAC also imports components and already reports tariff exposure.
https://www.merlintrader.com/ai-optics-poet-aaoi-lite-cohr-commercial-proof-2026/
The optical cycle no longer needs to be defended only with bandwidth forecasts. Large suppliers are already showing the demand in revenue, margins and forward guidance. That changes the question for earlier-stage $POET: the next proof is not another addressable-market slide, but the conversion of purchase orders and qualifications into shipped products, recognized revenue, repeat business and eventually gross profit.
YARTEMLEA generated $28.5 million of Q2 net revenue, up from $9.9 million in Q1, and Omeros reached reported operating breakeven. The June cash figure precedes July convertible-note repurchases with an aggregate $60.2 million purchase price plus approximately $0.2 million of accrued interest, so commercial momentum and post-transaction liquidity must be read together.
https://www.merlintrader.com/us-drone-tariffs-2026-supply-chain-map/
A 100 percent Section 232 duty lands on September 3, 2026, a 25 percent component tier is deferred to February 9, 2027, and export controls loosened on the same day the tariff was signed. What the three annexes actually cover, which layer of the supply chain each company occupies, and a five-question routine for reading the next announcement.
https://www.merlintrader.com/run-up-biotech-masterclass/
5 Chapters, totally free.